Fig. 1



radical surgery of gastric cancer or colic cancer
evaluated in outpatient care
Pre
1-wk
2-wk
4-wk
6-wk
within 6 weeks from surgery
4 weeks TS-1 standard therapy (oral) (first course)
drug withdrawal for 2 weeks
4 weeks TS-1 standard therapy (oral) (second course)
5 weeks ingestion of supplement containing cystine and theanin

Fig. 2



Control
Cystine and theanine
Neutrophil counts (/mm3)
3500
3000
2500
2000
1500
Pre
2-wk
Time after chemotherapy

Fig. 3



Control
Cystine and theanine
Relative change of neutrophil counts (/Pre)
1.2
1.0
0.8
0.6
Pre
2-wk
Time after chemotherapy

Fig. 4



4000
3500
3000
2500
2000
Neutrophil counts (/mm3)
***
Pre
2-wk
Time after chemotherapy
Control
Cystine and theanine
*** P<0.001 (Paired t-test)

Fig. 5



1.2
1.1
1.0
0.9
0.8
0.7
Relative change of neutrophil counts (/Pre)
†
Pre
2-wk
Time after chemotherapy
Control
Cystine and theanine
† P<0.1 (t-test)

Fig. 6



Incidence rate of adverse events of grade 2 or more (%)
30
20
10
0
Control
Cystine and theanine
Neutropenia
Anorexia
Nausea
Diarrhea
Malaise

Fig. 7



Incidence rate of adverse events of grade 2 or more (%)
40
30
20
10
0
Control
Cystine and theanine
Neutropenia

Fig. 8



40
30
20
10
0
Incidence rate of adverse events of grade 2 or more (%)
Control
Cystine and theanine
**
†
Stomatitis
Anorexia
Nausea
Diarrhea
Malaise
Exanthema
** P<0.05, † P<0.1 (Fisher's exact test)

Fig. 9



70
60
50
40
30
20
10
0
Completion rate of chemotherapy (%)
Control
Cystine and theanine

Fig. 10




** P<0.01 (Fisher's exact test)
**
Completion rate of chemotherapy (%)
80
70
60
50
40
30
20
10
0
Control
Cystine and theanine

Fig. 11


** P<0.01 (t-test)
**
Period during which entire dose was able to be taken (day)
30
25
20
15
10
5
0
Control
Cystine and theanine